LENSAR (LNSR) Price & Analysis

Compare

72 Followers

LNSR Stock Chart & Stats

$12.28

-$0.54(-6.29%)

At close: Jan 08 4:00 PM EST

$12.28

-$0.54(-6.29%)

Day’s Range― - ―

52-Week Range$6.52 - $17.31

Previous CloseN/A

Volume40.10K

Average Volume (3M)42.04K

Market Cap

$145.13M

Enterprise Value$153.02M

Total Cash (Recent Filing)$16.87M

Total Debt (Recent Filing)$2.88M

Price to Earnings (P/E)―

Beta0.71

Next Earnings

Mar 10, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.31

Shares Outstanding11,934,784

10 Day Avg. Volume41,933

30 Day Avg. Volume42,039

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)21.18

Price to Sales (P/S)1.92

P/FCF Ratio-42.36

Enterprise Value/Market Cap1.05

Enterprise Value/Revenue2.59

Enterprise Value/Gross Profit5.61

Enterprise Value/Ebitda-8.77

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

AcquisitionThe announced acquisition by Alcon is seen as a positive outcome for both Lensar and Alcon, with Lensar experiencing strong adoption of its ALLY System in the cataract surgery market.

Market ExpansionLNSR highlighted that ~75% of US FY24 placements have come from new customers, indicating strong market expansion and competitive positioning.

Bears Say

Fair ValuationThe stock is rated as Neutral because the implied takeout value is seen as fairly valued, indicating limited upside potential.

Growth ChallengesLensar is required to achieve substantial procedure growth to meet the terms of the acquisition agreement, which may pose challenges.

LENSAR News

Lensar reports Q3 EPS (31c) vs. (13c) last year

Reports Q3 revenue $14.3M vs. $13.5M last year. “We are pleased with the continued adoption of ALLY both...

6d ago

LNSR

LENSAR Reports Growth Amid Acquisition Developments

Lensar Inc ( ($LNSR) ) has released its Q3 earnings. Here is a breakdown of the information Lensar...

5d ago

LNSR

LENSAR Announces Virtual Annual Meeting Plans

An update from LENSAR ( ($LNSR) ) is now available. LENSAR, Inc. has announced that its 2025 annual...

21d ago

LNSR

Needham medtech & diagnostics analysts hold analyst/industry conference call

Med Tech & Diagnostics Analysts Saxon and Matson, along with Dr. Yuna Rapoport of Manhattan Eye, provide a...

2M ago

ALC

JNJ

Lensar Inc. Reports Growth Amid Merger Progress

Lensar Inc ( ($LNSR) ) has released its Q2 earnings. Here is a breakdown of the information Lensar...

3M ago

LNSR

Lensar reports Q2 EPS (15c) vs (79c) last year

Reports Q2 revenue $13.935M vs $12.636M last year. “Our second quarter results reflect the continued, strong momentum of...

3M ago

LNSR

LENSAR Stockholders Approve Merger with Alcon Research

LENSAR ( ($LNSR) ) has issued an update. On July 2, 2025, LENSAR, Inc. held a virtual special...

4M ago

LNSR

FTC Extends Waiting Period for LENSAR Merger

LENSAR ( ($LNSR) ) just unveiled an update. On March 23, 2025, LENSAR, Inc. entered into a merger...

6M ago

LNSR

LENSAR Announces Merger with Alcon Research

New activity is brewing for LENSAR ( ($LNSR) ). The company has submitted a Form DEFM14A to the...

6M ago

LNSR

LENSAR Reports Strong Q1 2025 Growth Amid Merger Plans

Lensar Inc ( ($LNSR) ) has released its Q1 earnings. Here is a breakdown of the information Lensar...

6M ago

LNSR

Lensar reports Q1 EPS ($2.32) vs. (19c) last year

Reports Q1 revenue $14.2M vs. $10.6M last year.”We had a solid start to 2025, as we successfully placed...

6M ago

LNSR

Lensar downgraded to Hold from Buy at Lake Street

Lake Street analyst Frank Takkinen downgraded Lensar (LNSR) to Hold from Buy with a price target of $15,...

8M ago

LNSR

Lensar downgraded to Neutral from Buy at BTIG

BTIG downgraded Lensar (LNSR) to Neutral from Buy following the announcement that Alcon (ALC) agreed to acquire the...

8M ago

LNSR

Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit

Stock index futures are experiencing a notable surge, reflecting renewed investor optimism, primarily driven by reports suggesting that...

8M ago

ALC

LNSR FAQ

What was Lensar Inc’s price range in the past 12 months?

Lensar Inc lowest stock price was $6.52 and its highest was $17.31 in the past 12 months.

What is Lensar Inc’s market cap?

Lensar Inc’s market cap is $145.13M.

When is Lensar Inc’s upcoming earnings report date?

Lensar Inc’s upcoming earnings report date is Mar 10, 2026 which is in 118 days.

How were Lensar Inc’s earnings last quarter?

Lensar Inc released its earnings results on Nov 06, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.31.

Is Lensar Inc overvalued?

According to Wall Street analysts Lensar Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lensar Inc pay dividends?

Lensar Inc does not currently pay dividends.

What is Lensar Inc’s EPS estimate?

Lensar Inc’s EPS estimate is -0.07.

How many shares outstanding does Lensar Inc have?

Lensar Inc has 11,934,784 shares outstanding.

What happened to Lensar Inc’s price movement after its last earnings report?

Lensar Inc reported an EPS of -$0.31 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.626%.

Which hedge fund is a major shareholder of Lensar Inc?

Currently, no hedge funds are holding shares in LNSR

LENSAR Stock Smart Score

Underperform

Fundamentals

Return on Equity

-422.35%

Trailing 12-Months

Asset Growth

14.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Lensar Inc

LENSAR, Inc. is a medical technology company specializing in advanced ophthalmic surgical solutions, primarily focused on cataract surgery. The company develops and markets the LENSAR Laser System, which utilizes precision laser technology to enhance the efficiency and accuracy of cataract procedures. By integrating digital imaging and advanced software, LENSAR aims to improve patient outcomes and streamline the surgical process for ophthalmic surgeons.